{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:19:41Z","timestamp":1794745181758,"version":"4.9.1"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["43017425"],"award-info":[{"award-number":["43017425"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.biopha.2026.119975","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:39:41Z","timestamp":1791304781000},"page":"119975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mechanism\u2011targeted therapies for vestibular schwannoma: Emerging molecular pathways and translational horizons"],"prefix":"10.1016","volume":"204","author":[{"given":"Shahrokh","family":"Khoshsirat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5032-4595","authenticated-orcid":false,"given":"Negar","family":"Naderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8476-9487","authenticated-orcid":false,"given":"Forouzan","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila Mohaghegh","family":"Shalmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4950-466X","authenticated-orcid":false,"given":"Safura","family":"Pournajaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.biopha.2026.119975_bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2147\/CLEP.S218670","article-title":"Epidemiology of vestibular schwannomas\u2013prospective 40-year data from an unselected national cohort","author":"Reznitsky","year":"2019","journal-title":"Clin. Epidemiol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119975_bib3","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/jmg.40.11.802","article-title":"Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation","volume":"40","author":"Warren","year":"2003","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1083\/jcb.200503165","article-title":"Merlin\/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane","volume":"171","author":"Okada","year":"2005","journal-title":"J. Cell. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119975_bib5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1097\/MAO.0b013e318298ac79","article-title":"NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications","volume":"34","author":"Lassaletta","year":"2013","journal-title":"Otol. Neurotol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib6","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/hmg\/3.2.347","article-title":"Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma","volume":"3","author":"Irving","year":"1994","journal-title":"Hum. Mol. Genet."},{"issue":"9","key":"10.1016\/j.biopha.2026.119975_bib7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmg-2024-110065","article-title":"NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study","volume":"61","author":"Forde","year":"2024","journal-title":"J. Med. Genet."},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.3171\/2015.12.JNS151857","article-title":"A matched cohort comparison of clinical outcomes following microsurgical resection or stereotactic radiosurgery for patients with small- and medium-sized vestibular schwannomas","volume":"125","author":"Golfinos","year":"2016","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.biopha.2026.119975_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2023.1216093","article-title":"Recurrences and progression following microsurgery of vestibular schwannoma","volume":"10","author":"Scheer","year":"2023","journal-title":"Front. Surg."},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.joto.2017.08.002","article-title":"Wait and scan\u201d management of patients with vestibular schwannoma and the relevance of non-contrast MRI in the follow-up","volume":"12","author":"Zou","year":"2017","journal-title":"J. Otol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/neuonc\/noz153","article-title":"EANO guideline on the diagnosis and treatment of vestibular schwannoma","volume":"22","author":"Goldbrunner","year":"2020","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib12","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/cimb48030292","article-title":"Targeted Medical Therapy for Vestibular Schwannomas: Evidence, Limits, and Future Directions\u2014A Scoping Review","volume":"48","author":"Arsie","year":"2026","journal-title":"Curr. Issues Mol. Biol."},{"issue":"14","key":"10.1016\/j.biopha.2026.119975_bib13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJMra2020394","article-title":"Vestibular schwannomas","volume":"384","author":"Carlson","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3171\/2011.6.JNS11131","article-title":"The molecular biology and novel treatments of vestibular schwannomas: a review","volume":"115","author":"Fong","year":"2011","journal-title":"J. Neurosurg."},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00106-016-0201-3","article-title":"[Pathogenesis and molecular pathology of vestibular schwannoma]","volume":"65","author":"Brodhun","year":"2017","journal-title":"HNO"},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bpa.12125","article-title":"Schwannomas and Their Pathogenesis","volume":"24","author":"Hilton","year":"2014","journal-title":"Brain Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/jwas.jwas_177_24","article-title":"Histomorphological Spectrum and Diagnostic Utility of S100, SOX10, CD34, Calretinin, and Ki67 in the Evaluation of Schwannomas: A Retrospective Study of 26 Cases in a Tertiary Health Institute, Zaria-Nigeria","volume":"16","author":"Adamu","year":"2025","journal-title":"J. West. Afr. Coll. Surg."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib18","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1017\/S0022215107001028","article-title":"Nerve origin of vestibular schwannoma: a prospective study","volume":"122","author":"Khrais","year":"2007","journal-title":"J. Laryngol. & Otol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.mao.0000180484.24242.54","article-title":"The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level","volume":"27","author":"Neff","year":"2006","journal-title":"Otol. Neurotol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17030393","article-title":"Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas","volume":"17","author":"Douwes","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","article-title":"Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus","volume":"140","author":"Li","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119975_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2025.1662274","article-title":"Schwann cells in the inner ear: development, disease, and regeneration","volume":"19","author":"Montigny","year":"2025","journal-title":"Front. Cell. Neurosci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad197","article-title":"The comparable tumour microenvironment in sporadic and NF2-related schwannomatosis vestibular schwannoma","volume":"5","author":"Gregory","year":"2023","journal-title":"Brain Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib24","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13287-025-04281-x","article-title":"Interactions among Merlin, Arkadia, and SKOR2 mediate NF2-associated human Schwann cell proliferation","volume":"16","author":"Tang","year":"2025","journal-title":"Stem Cell. Res. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2026.119975_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41419-023-06141-z","article-title":"Hearing loss and vestibular schwannoma: new insights into Schwann cells implication","volume":"14","author":"Mohamed","year":"2023","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12974-025-03364-z","article-title":"Immune profiling of human vestibular schwannoma secretions identifies TNF-\u03b1 and TWEAK as cytokines with synergistic potential to impair hearing","volume":"22","author":"Vasilijic","year":"2025","journal-title":"J. Neuroinflamm."},{"issue":"7","key":"10.1016\/j.biopha.2026.119975_bib27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.molonc.2015.03.009","article-title":"Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth","volume":"9","author":"Dilwali","year":"2015","journal-title":"Mol. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119975_bib28","first-page":"1498","article-title":"Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells","volume":"18","author":"Soares","year":"2016","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10689-025-00486-4","article-title":"SMARCB1-related schwannomatosis and other SMARCB1-associated phenotypes: clinical spectrum and molecular pathogenesis","volume":"24","author":"Kehrer-Sawatzki","year":"2025","journal-title":"Fam. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2026.119975_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115850","article-title":"Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis","volume":"22","author":"Tamura","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib31","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/lary.20834","article-title":"Angiogenesis in vestibular schwannomas: expression of extracellular matrix factors MMP-2, MMP-9, and TIMP-1","volume":"120","author":"M\u00f8ller","year":"2010","journal-title":"Laryngoscope"},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib32","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000346238","article-title":"The VEGF\/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence","volume":"74","author":"Koutsimpelas","year":"2013","journal-title":"ORL"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib33","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3892\/mmr.2015.3415","article-title":"Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue","volume":"12","author":"Taurone","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2026.119975_bib34","article-title":"Potential molecular biomarkers of vestibular schwannoma growth: progress and prospects","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119975_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.984529","article-title":"Single-cell sequencing reveals the cell map and transcriptional network of sporadic vestibular schwannoma","author":"Yidian","year":"2022","journal-title":"Front. Mol. Neurosci. [Internet]"},{"key":"10.1016\/j.biopha.2026.119975_bib36","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1016\/j.wneu.2020.07.208","article-title":"Immunohistochemical Profiles of Matrix Metalloproteinases and Vascular Endothelial Growth Factor Overexpression in the Antoni B Area of Vestibular Schwannomas","volume":"144","author":"Xia","year":"2020","journal-title":"World Neurosurg."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/15384047.2014.972765","article-title":"Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells","volume":"16","author":"Dilwali","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib38","article-title":"Matrix metalloproteinase 9: An emerging biomarker for classification of adherent vestibular schwannoma","volume":"6","author":"Nguyen","year":"2024","journal-title":"Neurooncol Adv."},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib39","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3171\/jns.2007.106.5.866","article-title":"Cystic vestibular schwannomas: a possible role of matrix metalloproteinase\u20132 in cyst development and unfavorable surgical outcome","volume":"106","author":"Moon","year":"2007","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib40","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/MAO.0000000000004073","article-title":"Identifying Tumor Microenvironment Biomarkers in Adherent and Cystic Vestibular Schwannomas","volume":"45","author":"Zhang","year":"2024","journal-title":"Otol. Neurotol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10142-019-00672-5","article-title":"Gene expression profiles between cystic and solid vestibular schwannoma indicate susceptible molecules and pathways in the cystic formation of vestibular schwannoma","volume":"19","author":"Yan","year":"2019","journal-title":"Funct. Integr. Genom."},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib42","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00428-012-1236-9","article-title":"Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas","volume":"460","author":"De Vries","year":"2012","journal-title":"Virchows Arch."},{"key":"10.1016\/j.biopha.2026.119975_bib43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fncel.2020.00191","article-title":"MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas","volume":"14","author":"Ren","year":"2020","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.biopha.2026.119975_bib44","first-page":"2025","article-title":"Potential target within the tumor microenvironment - MT1-MMP","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol. [Internet]"},{"issue":"7","key":"10.1016\/j.biopha.2026.119975_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076522","article-title":"Tumor Microenvironment in Sporadic Vestibular Schwannoma: A Systematic, Narrative Review","volume":"24","author":"Cazzador","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11010032","article-title":"Tumor Biology and Microenvironment of Vestibular Schwannoma-Relation to Tumor Growth and Hearing Loss","volume":"11","author":"Tesa\u0159ov\u00e1","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib47","article-title":"The inflammatory microenvironment in vestibular schwannoma","volume":"2","author":"Hannan","year":"2020","journal-title":"Neurooncol Adv."},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/neuonc\/noy177","article-title":"Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma","volume":"21","author":"Lewis","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biopha.2026.119975_bib49","first-page":"2024","article-title":"Analysis of tumor microenvironment composition in vestibular schwannomas: insights into NF2-associated and sporadic variations and their clinical correlations","volume":"14","author":"Nickl","year":"2024","journal-title":"Front. Oncol. [Internet]"},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib50","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MAO.0b013e31827c9fbf","article-title":"Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas","volume":"34","author":"de Vries","year":"2013","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.biopha.2026.119975_bib51","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.2147\/JIR.S476745","article-title":"Exploring the Role of Inflammatory Genes and Immune Infiltration in Vestibular Schwannomas Pathogenesis","volume":"17","author":"Gan","year":"2024","journal-title":"J. Inflamm. Res."},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030466","article-title":"Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the T\u00fcbingen Schwannoma Cohort","volume":"13","author":"Gon\u00e7alves","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/2473974X211059111","article-title":"Tumor-Associated Macrophages in Vestibular Schwannoma and Relationship to Hearing","volume":"5","author":"Nisenbaum","year":"2021","journal-title":"OTO Open."},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib54","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3171\/2020.3.JNS193230","article-title":"The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study","volume":"134","author":"Lewis","year":"2021","journal-title":"J. Neurosurg."},{"issue":"10","key":"10.1016\/j.biopha.2026.119975_bib55","article-title":"Immunophenotype of Vestibular Schwannomas","volume":"41","author":"Bi","year":"2020","journal-title":"Otol. & Neurotol. [Internet]"},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib56","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0006-291X(02)02077-6","article-title":"Inhibition of NF-kappaB activation by merlin","volume":"296","author":"Kim","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2026.119975_bib57","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.biopha.2017.08.085","article-title":"The anti-tumor effect of aspirin: What we know and what we expect","volume":"95","author":"Ma","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib58","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1227\/NEU.0b013e318208f5c7","article-title":"Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas","volume":"68","author":"Hong","year":"2011","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13046-022-02473-4","article-title":"Distinct immune signature predicts progression of vestibular schwannoma and unveils a possible viral etiology","volume":"41","author":"Amit","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib60","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae400","article-title":"Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma","volume":"6","author":"Gregory","year":"2024","journal-title":"Brain Commun."},{"issue":"9","key":"10.1016\/j.biopha.2026.119975_bib61","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ajpath.2022.06.006","article-title":"Single-Cell RNA-Seq Reveals Heterogeneity of Cell Communications between Schwann Cells and Fibroblasts within Vestibular Schwannoma Microenvironment","volume":"192","author":"Xu","year":"2022","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib62","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41467-023-42762-w","article-title":"Single-cell multi-omic analysis of the vestibular schwannoma ecosystem uncovers a nerve injury-like state","volume":"15","author":"Barrett","year":"2024","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.biopha.2026.119975_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cells13191669","article-title":"Cancer-Associated Fibroblast Subtypes Reveal Distinct Gene Signatures in the Tumor Immune Microenvironment of Vestibular Schwannoma","volume":"13","author":"Sung","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/s41698-025-01028-y","article-title":"Integrating single-cell and spatial transcriptomics reveals the cellular heterogeneity of vestibular schwannoma","volume":"9","author":"Dong","year":"2025","journal-title":"npj Precis. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib65","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11060-022-04221-2","article-title":"Multiplatform molecular analysis of vestibular schwannoma reveals two robust subgroups with distinct microenvironment","volume":"161","author":"Landry","year":"2023","journal-title":"J. Neurooncol"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib66","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1038\/s41467-025-57586-z","article-title":"Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma","volume":"16","author":"Jones","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib67","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ohn.1018","article-title":"Quantitative Assessment of Collagen Architecture to Determine Role of Tumor Stroma During Vestibular Schwannoma Progression","volume":"172","author":"Fisher","year":"2025","journal-title":"Otolaryngol. Head. Neck Surg."},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib68","first-page":"S1","article-title":"Immune Profiling of Secreted Factors from Human Vestibular Schwannoma Cells and Tumor-associated Macrophages","volume":"134","author":"Stankovic","year":"2024","journal-title":"Laryngoscope"},{"key":"10.1016\/j.biopha.2026.119975_bib69","doi-asserted-by":"crossref","DOI":"10.1007\/s00405-026-10174-3","article-title":"Efficacy and safety of bevacizumab for vestibular schwannomas in neurofibromatosis type-2: a systematic review and meta-analysis","author":"Khanmirzaei","year":"2026","journal-title":"Eur. Arch. Otorhinolaryngol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib70","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MAO.0000000000001781","article-title":"Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2","volume":"39","author":"Huang","year":"2018","journal-title":"Otol. Neurotol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119975_bib71","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/neuonc\/noad066","article-title":"Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma","volume":"25","author":"Plotkin","year":"2023","journal-title":"Neuro Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib72","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s11060-025-05100-2","article-title":"Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab","volume":"174","author":"Ahlawat","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.biopha.2026.119975_bib73","first-page":"2024","article-title":"VEGFR-3 signaling in macrophages: friend or foe in disease?","volume":"15","author":"Kannan","year":"2024","journal-title":"Front. Immunol. [Internet]"},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib74","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11060-026-05574-8","article-title":"Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model","volume":"177","author":"Lu","year":"2026","journal-title":"J. Neurooncol"},{"issue":"9","key":"10.1016\/j.biopha.2026.119975_bib75","doi-asserted-by":"crossref","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","article-title":"Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models","volume":"115","author":"Zhao","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-025-02033-1","article-title":"Targeting HGF\/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion","volume":"23","author":"Xia","year":"2025","journal-title":"Cell. Commun. Signal."},{"issue":"9","key":"10.1016\/j.biopha.2026.119975_bib77","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/lary.27114","article-title":"Aspirin does not prevent growth of vestibular schwannomas: A case-control study","volume":"128","author":"MacKeith","year":"2018","journal-title":"Laryngoscope"},{"issue":"8","key":"10.1016\/j.biopha.2026.119975_bib78","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1097\/MAO.0000000000001506","article-title":"Vestibular Schwannoma Growth With Aspirin and Other Nonsteroidal Anti-inflammatory Drugs","volume":"38","author":"Hunter","year":"2017","journal-title":"Otol. Neurotol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib79","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/0194599819827812","article-title":"Impact of Aspirin and Other NSAID Use on Volumetric and Linear Growth in Vestibular Schwannoma","volume":"160","author":"Marinelli","year":"2019","journal-title":"Otolaryngol. Head. Neck Surg."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib80","article-title":"Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double-Blind, Placebo-Controlled Study Proposal","volume":"10","author":"Welling","year":"2025","journal-title":"Laryngoscope Investig. Otolaryngol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib81","article-title":"Phase II study of axitinib in patients with NF2-related schwannomatosis and progressive vestibular schwannomas","volume":"7","author":"Garcia","year":"2025","journal-title":"Neurooncol Adv."},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib82","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0033-1338262","article-title":"Antiangiogenic agents for nonmalignant brain tumors","volume":"74","author":"Hawasli","year":"2013","journal-title":"J. Neurol. Surg. B Skull Base"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib83","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MAO.0b013e3182009665","article-title":"Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma","volume":"32","author":"Altuna","year":"2011","journal-title":"Otol. Neurotol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039412","article-title":"Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells","volume":"7","author":"Sabha","year":"2012","journal-title":"PLoS. One"},{"issue":"3","key":"10.1016\/j.biopha.2026.119975_bib85","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.otc.2023.02.004","article-title":"Updates on Tumor Biology in Vestibular Schwannoma","volume":"56","author":"Nourbakhsh","year":"2023","journal-title":"Otolaryngol. Clin. North. Am."},{"key":"10.1016\/j.biopha.2026.119975_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.heares.2019.07.007","article-title":"NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss","volume":"381","author":"Sagers","year":"2019","journal-title":"Hear. Res."},{"key":"10.1016\/j.biopha.2026.119975_bib87","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1038\/s41598-018-23609-7","article-title":"Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma","volume":"8","author":"Sagers","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119975_bib88","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib89","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/MAO.0b013e31823e287f","article-title":"Treatment of vestibular schwannoma cells with ErbB inhibitors","volume":"33","author":"Bush","year":"2012","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.biopha.2026.119975_bib90","doi-asserted-by":"crossref","unstructured":"Ronellenfitsch M.W., Harter P.N., Kirchner M., Heining C., Hutter B., Gieldon L., et al. Targetable ERBB2 mutations identified in neurofibroma\/schwannoma hybrid nerve sheath tumors. J Clin Invest. 130(5):2488\u20132495. doi:10.1172\/JCI130787 PubMed PMID: 32017710; PubMed Central PMCID: PMC7190903.","DOI":"10.1172\/JCI130787"},{"issue":"8","key":"10.1016\/j.biopha.2026.119975_bib91","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/neuonc\/noq012","article-title":"ErbB\/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma","volume":"12","author":"Ammoun","year":"2010","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119975_bib92","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.semcdb.2010.08.008","article-title":"Nrg1\/ErbB signaling networks in Schwann cell development and myelination","volume":"21","author":"Newbern","year":"2010","journal-title":"Semin. Cell. Dev. Biol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib93","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/glia.20316","article-title":"Constitutive neuregulin-1\/ErbB signaling contributes to human vestibular schwannoma proliferation","volume":"53","author":"Hansen","year":"2006","journal-title":"Glia"},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib94","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/MAO.0b013e31817f7398","article-title":"The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study","volume":"29","author":"Clark","year":"2008","journal-title":"Otol. Neurotol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119975_bib95","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1002\/j.1460-2075.1995.tb00101.x","article-title":"Heregulin-dependent regulation of HER2\/neu oncogenic signaling by heterodimerization with HER3","volume":"14","author":"Wallasch","year":"1995","journal-title":"EMBO J."},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib96","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/MAO.0b013e31821f7d88","article-title":"ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas","volume":"32","author":"Ahmad","year":"2011","journal-title":"Otol. Neurotol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib97","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3171\/2022.9.JNS22699","article-title":"Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"138","author":"Zhao","year":"2023","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.biopha.2026.119975_bib98","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuroscience.2021.12.035","article-title":"Circ_0001665 Contributes to the Occurrence of Vestibular Schwannoma via Targeting miR-302a-3p\/Adam9\/EGFR Signaling Pathway","volume":"490","author":"Wu","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2026.119975_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217146","article-title":"ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance","volume":"599","author":"Chen","year":"2024","journal-title":"Cancer Lett."},{"issue":"12","key":"10.1016\/j.biopha.2026.119975_bib100","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1073\/pnas.1016140108","article-title":"Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase","volume":"108","author":"Garrett","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119975_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118237","article-title":"The mTOR pathway in Gliomas: From molecular insights to targeted therapies","volume":"189","author":"Pournajaf","year":"2025","journal-title":"Biomed. & Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib102","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s12035-025-05653-3","article-title":"The mTOR Pathway in Hearing Disorders: Mechanistic Links to Aging, Regeneration, and Neurodegeneration","volume":"63","author":"Pournajaf","year":"2026","journal-title":"Mol. Neurobiol."},{"issue":"15","key":"10.1016\/j.biopha.2026.119975_bib103","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol. Cell. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib104","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","article-title":"Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types","volume":"10","author":"James","year":"2012","journal-title":"Mol. Cancer Res."},{"issue":"52","key":"10.1016\/j.biopha.2026.119975_bib105","doi-asserted-by":"crossref","first-page":"18200","DOI":"10.1073\/pnas.0405971102","article-title":"Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L","volume":"101","author":"Rong","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib106","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/lary.22392","article-title":"Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas","volume":"122","author":"Jacob","year":"2012","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281876","article-title":"Merlin tumor suppressor function is regulated by PIP2-mediated dimerization","volume":"18","author":"Hennigan","year":"2023","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010177","article-title":"Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis","volume":"12","author":"Gugel","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119975_bib109","first-page":"471","article-title":"A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2","volume":"6","author":"Petrilli","year":"2014","journal-title":"Am. J. Transl. Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119975_bib110","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1158\/1535-7163.MCT-23-0135","article-title":"Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells","volume":"22","author":"Hardin","year":"2023","journal-title":"Mol. Cancer Ther."},{"issue":"13","key":"10.1016\/j.biopha.2026.119975_bib111","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41388-024-02958-w","article-title":"Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis","volume":"43","author":"Nagel","year":"2024","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.biopha.2026.119975_bib112","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.ejca.2009.03.013","article-title":"Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells","volume":"45","author":"Lee","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib113","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib114","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.biopha.2026.119975_bib115","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/oncotarget.28254","article-title":"CUDC907, a dual phosphoinositide-3 kinase\/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells","volume":"13","author":"Huegel","year":"2022","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib116","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.3390\/ijms27062636","article-title":"Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells","volume":"27","author":"Nagel","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib117","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/MAO.0000000000003556","article-title":"Effect of AR42 in Primary Vestibular Schwannoma Cells and a Xenograft Model of Vestibular Schwannoma","volume":"43","author":"Misztal","year":"2022","journal-title":"Otol. Neurotol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119975_bib118","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.febslet.2012.03.016","article-title":"Merlin, a multi-suppressor from cell membrane to the nucleus","volume":"586","author":"Zhou","year":"2012","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.biopha.2026.119975_bib119","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib120","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","article-title":"Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac","volume":"67","author":"Morrison","year":"2007","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib121","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.biopha.2026.119975_bib122","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/lary.23472","article-title":"Inhibition of MEK pathway in vestibular schwannoma cell culture","volume":"122","author":"Neff","year":"2012","journal-title":"Laryngoscope"},{"issue":"36","key":"10.1016\/j.biopha.2026.119975_bib123","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1038\/s41388-019-0883-6","article-title":"The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling","volume":"38","author":"Cui","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib124","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.expneurol.2009.04.019","article-title":"PAK kinase regulates Rac GTPase and is a potential target in human schwannomas","volume":"218","author":"Flaiz","year":"2009","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib125","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","article-title":"Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac","volume":"67","author":"Morrison","year":"2007","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib126","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.bbrc.2005.12.122","article-title":"Merlin inhibits growth hormone-regulated Raf\u2013ERKs pathways by binding to Grb2 protein","volume":"340","author":"Lim","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2026.119975_bib127","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.18632\/oncotarget.659","article-title":"Ras\/Raf\/MEK\/ERK and PI3K\/PTEN\/Akt\/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance","volume":"3","author":"McCubrey","year":"2012","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.biopha.2026.119975_bib128","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141514","article-title":"Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS\/MAPK signaling","volume":"5","author":"Chen","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119975_bib129","article-title":"Merlin\u2013YAP signaling: emerging mechanisms, functions, and therapeutic approaches","author":"Guo","year":"2025","journal-title":"Trends Cell. Biol."},{"key":"10.1016\/j.biopha.2026.119975_bib130","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.wneu.2018.06.010","article-title":"Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma","volume":"117","author":"Zhao","year":"2018","journal-title":"World Neurosurg."},{"key":"10.1016\/j.biopha.2026.119975_bib131","unstructured":"de Guibert J.G. Analysis of Hippo Pathway Signalling in Schwannoma and Meningioma [Internet]. University of Plymouth; 2023. Available from: https:\/\/books.google.com\/books?id=42-yzwEACAAJ."},{"issue":"12","key":"10.1016\/j.biopha.2026.119975_bib132","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/0008-5472.CAN-15-1144","article-title":"YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis","volume":"76","author":"Guerrant","year":"2016","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2026.119975_bib133","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/s12276-025-01551-9","article-title":"The multifaceted role of YAP in the tumor microenvironment and its therapeutic implications in cancer","volume":"57","author":"Kim","year":"2025","journal-title":"Exp. & Mol. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib134","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1101\/gad.2000111","article-title":"Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein","volume":"25","author":"Zhao","year":"2011","journal-title":"Genes. Dev."},{"issue":"188","key":"10.1016\/j.biopha.2026.119975_bib135","first-page":"pt6","article-title":"Merlin\/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression","volume":"4","author":"Cooper","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.biopha.2026.119975_bib136","doi-asserted-by":"crossref","unstructured":"Guo P., Li B., Dong W., Zhou H., Wang L., Su T., et al. PI4P-mediated solid-like Merlin condensates orchestrate Hippo pathway regulation. Science. 385(6709):eadf4478. doi:10.1126\/science.adf4478.","DOI":"10.1126\/science.adf4478"},{"issue":"6","key":"10.1016\/j.biopha.2026.119975_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib138","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41392-025-02142-w","article-title":"Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances","volume":"10","author":"Xue","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119975_bib139","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1593\/neo.111060","article-title":"Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt\/\u03b2-Catenin Signaling Linked to the PDGFR\/Src and Rac\/PAK Pathways","volume":"13","author":"Zhou","year":"2011","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119975_bib140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/\u03b2-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell."},{"issue":"10","key":"10.1016\/j.biopha.2026.119975_bib141","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/cdd.2016.54","article-title":"Merlin inhibits Wnt\/\u03b2-catenin signaling by blocking LRP6 phosphorylation","volume":"23","author":"Kim","year":"2016","journal-title":"Cell. Death Differ."},{"issue":"17","key":"10.1016\/j.biopha.2026.119975_bib142","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/onc.2010.20","article-title":"NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation","volume":"29","author":"Bosco","year":"2010","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.biopha.2026.119975_bib143","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41401-022-00908-4","article-title":"Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of \u03b2-catenin","volume":"43","author":"Kim","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.biopha.2026.119975_bib144","first-page":"1162","article-title":"MicroRNA-200a suppresses the Wnt\/\u03b2-catenin signaling pathway by interacting with \u03b2-catenin","volume":"40","author":"Su","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2026.119975_bib145","article-title":"Molecular biology and disease models of vestibular schwannomas: state of the art","volume":"212","author":"L","year":"2025","journal-title":"Handb. Clin. Neurol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119975_bib146","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/cancers18020224","article-title":"Advancements in preclinical models for NF2-related schwannomatosis research","volume":"18","author":"Zhang","year":"2026","journal-title":"Cancers"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226010115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226010115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:01:09Z","timestamp":1794744069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226010115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":146,"alternative-id":["S0753332226010115"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119975","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism\u2011targeted therapies for vestibular schwannoma: Emerging molecular pathways and translational horizons","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119975"}}